AIMS: The study aimed to assess whether violacein has antimicrobial activity on Staphylococcus epidermidis and synergistically modulates the action of commercially available antimicrobial drugs. METHODS AND RESULTS: Violacein showed excellent antimicrobial activity on biofilm-forming and nonbiofilm-forming S. epidermidis strains (ATCC 35984) (ATCC 12228), with bacteriostatic (MIC = 20 μg ml-1 and 10 μg ml-1 respectively) and bactericidal effects (MBC = 20 μg ml-1 for both strains), observed in short periods of exposure. The violacein bactericidal concentration led to S. epidermidis death after 2-3 h of exposure. Additionally, violacein synergistically modulated the activity of different antimicrobial classes on S. epidermidis ATCC 12228 (81·8%; n = 9) and on S. epidermidis ATCC 35984 (54·5%; n = 6), reducing the MIC of these antibiotics by up to 16-fold. CONCLUSION: Violacein shows excellent antimicrobial activity on S. epidermidis strains. SIGNIFICANCE AND IMPACT OF THE STUDY: Violacein shows the potential for the development of a new drug for the treatment of infections caused by S. epidermidis.
AIMS: The study aimed to assess whether violacein has antimicrobial activity on Staphylococcus epidermidis and synergistically modulates the action of commercially available antimicrobial drugs. METHODS AND RESULTS:Violacein showed excellent antimicrobial activity on biofilm-forming and nonbiofilm-forming S. epidermidis strains (ATCC 35984) (ATCC 12228), with bacteriostatic (MIC = 20 μg ml-1 and 10 μg ml-1 respectively) and bactericidal effects (MBC = 20 μg ml-1 for both strains), observed in short periods of exposure. The violacein bactericidal concentration led to S. epidermidis death after 2-3 h of exposure. Additionally, violacein synergistically modulated the activity of different antimicrobial classes on S. epidermidis ATCC 12228 (81·8%; n = 9) and on S. epidermidis ATCC 35984 (54·5%; n = 6), reducing the MIC of these antibiotics by up to 16-fold. CONCLUSION:Violacein shows excellent antimicrobial activity on S. epidermidis strains. SIGNIFICANCE AND IMPACT OF THE STUDY: Violacein shows the potential for the development of a new drug for the treatment of infections caused by S. epidermidis.
Authors: Ayed A Dera; Irfan Ahmad; Prasanna Rajagopalan; Mesfer Al Shahrani; Ahmed Saif; Mohammad Y Alshahrani; Yasser Alraey; Ahmad M Alamri; Sultan Alasmari; Mohammed Makkawi; Ali G Alkhathami; Gaffar Zaman; Abdulrahim Hakami; Razan Alhefzi; Mohammad A Alfhili Journal: Saudi Med J Date: 2021-02 Impact factor: 1.484
Authors: Elizabeth Bilsland; Tatyana A Tavella; Renata Krogh; Jamie E Stokes; Annabelle Roberts; James Ajioka; David R Spring; Adriano D Andricopulo; Fabio T M Costa; Stephen G Oliver Journal: BMC Biotechnol Date: 2018-04-11 Impact factor: 2.563
Authors: Francisco A Venegas; Gabriele Köllisch; Kerstin Mark; Wibke E Diederich; Andreas Kaufmann; Stefan Bauer; Max Chavarría; Juan J Araya; Alfonso J García-Piñeres Journal: Sci Rep Date: 2019-09-20 Impact factor: 4.379